{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:40:06Z","timestamp":1794408006814,"version":"4.9.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.44750","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T16:37:59Z","timestamp":1643042279000},"page":"e2144750","source":"Crossref","is-referenced-by-count":73,"title":["Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy"],"prefix":"10.1001","volume":"5","author":[{"given":"Kerstin","family":"Hellwig","sequence":"first","affiliation":[{"name":"Department of Neurology, St. Josef-Hospital\u2013Katholisches Klinikum Bochum, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Tokic","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Thiel","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Josef-Hospital\u2013Katholisches Klinikum Bochum, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Esters","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Josef-Hospital\u2013Katholisches Klinikum Bochum, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Spicher","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Josef-Hospital\u2013Katholisches Klinikum Bochum, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Timmesfeld","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea I.","family":"Ciplea","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Josef-Hospital\u2013Katholisches Klinikum Bochum, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Josef-Hospital\u2013Katholisches Klinikum Bochum, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Langer-Gould","sequence":"additional","affiliation":[{"name":"Department of Neurology, Los Angeles Medical Center, Southern California Permanente Medical Group, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"zoi211238r1","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"Pt 6","key":"zoi211238r2","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/brain\/awh152","article-title":"Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.","volume":"127","author":"Vukusic","year":"2004","journal-title":"Brain"},{"key":"zoi211238r3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000367640","article-title":"Pregnancy in multiple sclerosis.","volume":"72","author":"Hellwig","year":"2014","journal-title":"Eur Neurol"},{"issue":"10","key":"zoi211238r4","doi-asserted-by":"publisher","first-page":"e832","DOI":"10.1212\/WNL.0000000000005068","article-title":"Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: maternal risks.","volume":"90","author":"Portaccio","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"zoi211238r5","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1212\/WNL.0000000000005065","article-title":"Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era.","volume":"90","author":"Alroughani","year":"2018","journal-title":"Neurology"},{"key":"zoi211238r6","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012084","article-title":"Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis.","author":"Yeh","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"zoi211238r7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/1352458518816614","article-title":"Pregnancy and multiple sclerosis in the DMT era: a cohort study in Western Austria.","volume":"26","author":"Bsteh","year":"2020","journal-title":"Mult Scler"},{"issue":"1","key":"zoi211238r8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1352458516641775","article-title":"Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.","volume":"23","author":"Larochelle","year":"2017","journal-title":"Mult Scler"},{"issue":"2","key":"zoi211238r9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.msard.2013.10.001","article-title":"Pseudotumoral rebound of multiple sclerosis in a pregnant patient after stopping natalizumab.","volume":"3","author":"Verhaeghe","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"zoi211238r10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.03.013","article-title":"Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.","volume":"307","author":"Serafini","year":"2017","journal-title":"J Neuroimmunol"},{"issue":"22","key":"zoi211238r11","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1212\/WNL.0b013e318275979d","article-title":"Lethal multiple sclerosis relapse after natalizumab withdrawal.","volume":"79","author":"Rigau","year":"2012","journal-title":"Neurology"},{"issue":"15","key":"zoi211238r12","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1212\/WNL.0b013e318210e5d0","article-title":"Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?","volume":"76","author":"Hellwig","year":"2011","journal-title":"Neurology"},{"issue":"7","key":"zoi211238r13","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1177\/1352458508088916","article-title":"Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable.","volume":"14","author":"Heesen","year":"2008","journal-title":"Mult Scler"},{"issue":"10","key":"zoi211238r14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2015.1806","article-title":"Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses.","volume":"72","author":"Hellwig","year":"2015","journal-title":"JAMA Neurol"},{"issue":"6","key":"zoi211238r15","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1212\/WNL.40.6.971","article-title":"Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial.","volume":"40","author":"Noseworthy","year":"1990","journal-title":"Neurology"},{"issue":"6","key":"zoi211238r16","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/1352458514549401","article-title":"Significant clinical worsening after natalizumab withdrawal: predictive factors.","volume":"21","author":"Vidal-Jordana","year":"2015","journal-title":"Mult Scler"},{"issue":"1","key":"zoi211238r17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS.","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology"},{"issue":"17","key":"zoi211238r18","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"},{"issue":"22","key":"zoi211238r19","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.","volume":"76","author":"O\u2019Connor","year":"2011","journal-title":"Neurology"},{"issue":"8","key":"zoi211238r20","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1001\/jamaneurol.2014.1200","article-title":"Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).","volume":"71","author":"Clerico","year":"2014","journal-title":"JAMA Neurol"},{"issue":"3","key":"zoi211238r21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10072-013-1527-1","article-title":"Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.","volume":"35","author":"Melis","year":"2014","journal-title":"Neurol Sci"},{"issue":"2","key":"zoi211238r22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/ane.2014.130.issue-2","article-title":"What to expect after natalizumab cessation in a real-life setting.","volume":"130","author":"Salhofer-Polanyi","year":"2014","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"zoi211238r23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/archneurol.2009.304","article-title":"Interferon-gamma-producing T cells, pregnancy, and postpartum relapses of multiple sclerosis.","volume":"67","author":"Langer-Gould","year":"2010","journal-title":"Arch Neurol"},{"issue":"1","key":"zoi211238r24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis.","volume":"348","author":"Miller","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi211238r25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13063-017-1870-2","article-title":"Why clinical trial outcomes fail to translate into benefits for patients.","volume":"18","author":"Heneghan","year":"2017","journal-title":"Trials"},{"issue":"7","key":"zoi211238r26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab use during the third trimester of pregnancy.","volume":"71","author":"Haghikia","year":"2014","journal-title":"JAMA Neurol"},{"issue":"5","key":"zoi211238r27","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/1352458520912637","article-title":"Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.","volume":"27","author":"Demortiere","year":"2021","journal-title":"Mult Scler"},{"issue":"4","key":"zoi211238r28","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000734","article-title":"Rituximab, MS, and pregnancy.","volume":"7","author":"Smith","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"zoi211238r29","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000913","article-title":"Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany.","volume":"8","author":"K\u00fcmpfel","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"zoi211238r30","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000723","article-title":"Monoclonal antibody treatment during pregnancy and\/or lactation in women with MS or neuromyelitis optica spectrum disorder.","volume":"7","author":"Ciplea","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2788309\/hellwig_2022_oi_211238_1642112682.25297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T16:38:05Z","timestamp":1643042285000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2788309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.44750","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]}}}